Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28566293 | 0.72 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2737360 | 0.70 | GABRA1 (0.37) | — | |
| SCHEMBL2217031 | 0.69 | GABBR2 (0.38) | MEN1KMT2ANAPRT | |
| SCHEMBL15061221 | 0.69 | KMT2A (0.49) | MEN1KMT2AALDH1A1KCNQ3KCNQ2 | |
| SCHEMBL30567639 | 0.67 | MAPK1 (0.40) | MEN1KMT2AALDH1A1KCNQ3KCNQ2 | |
| SCHEMBL5762975 | 0.67 | MAPK1 (0.40) | MEN1KMT2AALDH1A1KCNQ3KCNQ2 | |
| SCHEMBL14979284 | 0.67 | CA12 (0.42) | MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL4649720 | 0.66 | CNR2 (0.37) | ALDH1A1KCNQ3KCNQ2MAPK1NPC1 | |
| SCHEMBL10623146 | 0.65 | TSHR (0.37) | ALDH1A1 | |
| SCHEMBL16446984 | 0.65 | CA12 (0.41) | MEN1KMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MEN1 3305/4885KMT2A 4416/4885ALDH1A1 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.